Theradiag Announces Improved Results for H1 2019 - Seite 2

Pierre Morgon, Chairman of the Theradiag Board of Directors added: “We have benefited from extraordinary income related to non-recurring sales over this period. Combined with the implementation of promising strategic partnerships, this will allow Theradiag to invest in order to step up growth in key strategic markets, particularly the United States, whilst maintaining operational profitability and improving it over the medium term. This is a crucial period for the company and one to which we are paying special attention.”

Strong revenue growth in theranostics driven by LISA TRACKER sales

Theradiag posted first-half 2019 revenues of €5.0 million, up 9% from €4.6 million in H1 2018.

Theranostics performed well and posted a 12% growth, primarily driven by LISA TRACKER kits for routine use, for which sales exceeded €2.0 million during the period (vs. €1.8 million in H1 2018). Sales in France in this segment were up sharply.

Sales generated through the distribution channels were up 27% compared to the same period last year, in line with the recently implemented distribution strategy and partnerships.

The partnership entered into with IDS during the first half, covering R&D and the exclusive distribution of TRACKER kits in 33 new countries (including Germany, Latin America and the Middle East) is well underway and is progressing according to plan. The development of the next generation of automated technologies is making progress and will speed up the automation of diagnostics and enable greater flexibility. Regarding the marketing of the innovative TRACKER range, training sessions have begun in certain priority areas and are being rolled out as planned. The launch of operations in the United States with our new partner HalioDx is well underway.

The Diagnostic In Vitro (IVD) business posted first-half revenue of €2.9 million, up 7%, including significant non-recurring instrumentation sales. This historical business line continues to benefit from the Group’s recognized innovation expertise among laboratories, but does not have as much potential as theranostics. The strategy in place for these global immunology solutions is to continue targeting niche specialties, such as genetics and male fertility, and to support internal and external quality control programs. This does not require any particular investment commitments.